actinium Ac 225 zadavotide guraxetan

A radioconjugate composed of zadavotide guraxetan, a human prostate-specific membrane antigen (PSMA)-targeting ligand linked to the bifunctional tmacrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), and conjugated to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration, actinium Ac 225 zadavotide guraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.